Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of apalutamide plus ADT before and after radical prostatectomy in high-risk localized or locally advanced prostate cancer
MOH_2019-06-24_007222Phase 3Recruiting
- Sponsor
- Janssen-Cilag
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing ADT + ERLEADA with ADT + placebo (2 arms). Primary endpoints: Pathologic complete response and Metastasis-free survival. Started Mar 2019; status: recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2019-06-24_007222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-24_007222.